CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

Table 3 Results of randomized placebo-controlled clinical trials with CGRP mAb for the treatment of difficult-to-treat migraine

	MHD	Exclusion by unremitting headaches	Study duration (weeks)	Failed preventives required	Treatment arms	N	MMD change versus placebo	Dropout ratio	Reference	Acronym
Fremanezumab	6-30	+	12	2-4	placebo	279		1%	Ferrari et al, 2019	FOCUS
					675mg	276	-3.1	0%
					225mg^a	283	-3.5	1%
Galcanezumab	4-30	+	12	2-4	placebo	230		0%	Mulleners et al, 2020	CONQUER
Galcanezumab	4-30	+	12	2-4	120mg (^b240mg)	232	-3.1	0%	Mulleners et al, 2020	CONQUER
Erenumab	4-14	-	12	2-4	placebo	125		0%	Reuter et al, 2018	LIBERTY
Erenumab	4-14	-	12	2-4	140mg	121	-1.6	0%	Reuter et al, 2018	LIBERTY
Eptinezumab	4-30	-		2-4	placebo	280	Recruiting			DELIVER
					100mg	280
					300mg	280

Unless indicated differently, dosing is monthly for erenumab, galcanezumab and fremanezumab 225mg and every 3 months for eptinezumab and fremanezumab 675mg
NA data not available, MHD monthly headache days, MMD monthly migraine days
^athe chronic migraine subgroup received 675mg at the first month
^bloading dosage

ISSN: 1129-2377